<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[59, 60] tested<br>[113, 115] tolerated,<br>[124, 131] correlation of plasma drug levels with inhibition<br>[151, 155] increases in CETP mass<br>[164, 166] CETP inhibition<br>[185, 188] Total plasma cholesterol<br>[197, 201] nonHDL-C,<br>[210, 215] low-density lipoprotein cholesterol<br>[220, 226] Apolipoprotein A-I and E<br>[237, 238] apoB<br>[248, 251] Cholesteryl ester content<br>[272, 274] CETP inhibition<br></td>
<td width=33%>
[126, 129] plasma drug levels<br>[153, 155] CETP mass<br>[164, 166] CETP inhibition<br>[185, 188] Total plasma cholesterol<br>[248, 251] Cholesteryl ester content<br>[272, 274] CETP inhibition<br></td>
<td width=33%>
[45, 48] density lipoprotein cholesterol<br>[113, 115] tolerated,<br>[124, 131] correlation of plasma drug levels with inhibition<br>[151, 155] increases in CETP mass<br>[164, 166] CETP inhibition<br>[185, 188] Total plasma cholesterol<br>[198, 201] -C,<br>[210, 215] low-density lipoprotein cholesterol<br>[222, 226] -I and E<br>[237, 238] apoB<br>[248, 252] Cholesteryl ester content decreased<br>[272, 274] CETP inhibition<br></td>
</tr>
